Correlation Between Virax Biolabs and Cynata Therapeutics
Can any of the company-specific risk be diversified away by investing in both Virax Biolabs and Cynata Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virax Biolabs and Cynata Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Virax Biolabs Group and Cynata Therapeutics Limited, you can compare the effects of market volatilities on Virax Biolabs and Cynata Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virax Biolabs with a short position of Cynata Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virax Biolabs and Cynata Therapeutics.
Diversification Opportunities for Virax Biolabs and Cynata Therapeutics
0.0 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Virax and Cynata is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Virax Biolabs Group and Cynata Therapeutics Limited in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cynata Therapeutics and Virax Biolabs is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virax Biolabs Group are associated (or correlated) with Cynata Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cynata Therapeutics has no effect on the direction of Virax Biolabs i.e., Virax Biolabs and Cynata Therapeutics go up and down completely randomly.
Pair Corralation between Virax Biolabs and Cynata Therapeutics
Given the investment horizon of 90 days Virax Biolabs Group is expected to generate 2.11 times more return on investment than Cynata Therapeutics. However, Virax Biolabs is 2.11 times more volatile than Cynata Therapeutics Limited. It trades about 0.03 of its potential returns per unit of risk. Cynata Therapeutics Limited is currently generating about 0.02 per unit of risk. If you would invest 409.00 in Virax Biolabs Group on September 12, 2024 and sell it today you would lose (228.00) from holding Virax Biolabs Group or give up 55.75% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Flat |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Virax Biolabs Group vs. Cynata Therapeutics Limited
Performance |
| Timeline |
| Virax Biolabs Group |
| Cynata Therapeutics |
Virax Biolabs and Cynata Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Virax Biolabs and Cynata Therapeutics
The main advantage of trading using opposite Virax Biolabs and Cynata Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virax Biolabs position performs unexpectedly, Cynata Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cynata Therapeutics will offset losses from the drop in Cynata Therapeutics' long position.| Virax Biolabs vs. Revelation Biosciences | Virax Biolabs vs. Kiora Pharmaceuticals | Virax Biolabs vs. Quoin Pharmaceuticals Ltd | Virax Biolabs vs. Neurobo Pharmaceuticals |
| Cynata Therapeutics vs. Forte Biosciences | Cynata Therapeutics vs. Cellectar Biosciences | Cynata Therapeutics vs. Virax Biolabs Group | Cynata Therapeutics vs. Revelation Biosciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Complementary Tools
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |